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a b s t r a c t
INTRODUCTION: Primary retroperitoneal extragonadal tumours relapsing after initial chemotherapy have
a poor prognosis.
PRESENTATIONOFTHECASE:Wereport a caseofprimary retroperitoneal embryonal carcinoma inapatient
with negative open testes biopsy. After the ﬁrst line of chemotherapy (4 cycles BEP) secondary surgery
with extirpation of a retroperitoneal residual mass was performed. The residuum proved histologically
to be a mature teratoma, and no adjuvant treatment was given according to current recommendations.
The patient had regular follow-up. 3.5 years later, patient developed recurrence in the ipsilateral adrenal
gland, which was treated with surgery and 4 cycles of salvage VeIP chemotherapy. Seven months after
the second surgical intervention the patient underwent multivisceral “desperation surgery” for early
metastatic disease progression followed by 2 cycles of salvage TIP chemotherapy. The patient is currently
disease-free at 34 months.
CONCLUSION: Initial postchemotherapy retroperitoneal lymph node dissection is crucial for local
retroperitoneal disease control. Aggressively treated metastatic recurrent disease does not preclude
prolonged survival. Despite a generally poor prognosis, repeated complex oncosurgical therapy for
retroperitoneal extragonadal tumours may be worthwhile.
© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Gonadal (GGCTs) and extragonadal germ cell tumours (EGGCTs)
originate from primordial germ cells. EGGCTs may develop by
malignant transformation of residual, misplaced primitive germ
cells in the sagittal midline, or may be a group of misdiagnosed
metastatic GGCTs [1]. Metastatic retroperitoneal tumours may
have their primary small and unrecognised, or spontaneously
regressed (autoinfarcted, burnt-out) [2–4].
Currently, 5% of malignant GGCTs are thought to be of extrag-
onadal origin [5]. Patients with EGGCTs are classiﬁed into good,
Abbreviations: GGCT, gonadal germ cell tumour; EGGCT, extragonadal germ cell
tumour; IGCCCG, International Germ Cell Cancer Collaborative Group; MDT, mul-
tidisciplinary team; BEP chemotherapy, chemotherapy with bleomycin, etoposid
and cisplatin; G-CSF prophylaxis, granulocyte-colony stimulating factor profylaxis;
VeIP chemotherapy, chemotherapy with vinblastine, ifosfamide and cisplatin; TIP
chemotherapy, chemotherapywithpaclitaxel, ifosfamid and cisplatin; EORTC, Euro-
pean Organisation for Research and Treatment of Cancer; PET/CT, positron emission
tomography–computed tomography; RPLND, retroperitoneal lymphadenectomy.
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intermediate and poor prognosis categories based on primary
tumour site, serum tumour marker levels and metastatic spread
[6,7]. While GGCTs are typically curable with a high ﬁve-year
survival rate (more than 90% when diagnosed at early stage)
[8], nonseminomatous, retroperitoneal EGGCTs present with poor
prognostic features in 50%, have frequent metastases in 76% and a
ﬁve-year survival rate of 62%. Based on therapy response rate (68%)
and a relapse rate of 50%, retroperitoneal EGGCTs are presumed to
belong to apoorprognosis groupeven if they fulﬁl the IGCCCGcrite-
ria for good, or intermediate prognosis [5]. Embryonal carcinoma is
an undifferentiated, pluripotent germinal cell neoplasm. This rare
and complex malignancy should be managed by an experienced
multidisciplinary team (MDT) in specialised centres [9].
2. Presentation of the case
A 42-year-old, obese (BMI 34.4 kgm−2), Caucasian male pre-
sented with left sided obstructive nephropathy due to a retroperi-
toneal primary in 10/2007. Retroperitoneal lymphadenopathy on
abdominal ultrasonography (USG) and computed tomography
(CT) raised suspicion of lymphoma (Fig. 1). After ureteral stent
placement laparoscopic biopsywas performed. The histopathology
http://dx.doi.org/10.1016/j.ijscr.2015.03.018
2210-2612/© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. (A) Metastatatic lesion of the right adrenal gland. (B) Interaortocaval and peripancreatic lymphadenopathy. (C) Bilateral metastatic retroperitoneal disease. (D)
Calciﬁcation in metastatic lesion below right renal vascular pedicle.
revealed a germinal tumour formed predominantly by embryonal
carcinoma cells (99%) and a small proportion of choriocarcinoma
cells (1%) (Fig. 2). Immunohistochemistry staining was positive for
CD30, PLAP and ßHCG (Fig. 3). Bilateral open testes biopsy proved
negative. Based on the CT, MRI, histopathology and tumour marker
level, the diseasewas staged as “intermediate risk” according to the
InternationalGermCell Cancer CollaborativeGroup (IGCCCG) crite-
ria. The case was presented at a multidisciplinary team conference
for consensus decision-making on multimodal treatment.
The patient was given a course of 1st-line BEP chemother-
apy (bleomycin 30 IU day 1, 8, and 15, etoposid 100mg/qm day
1–5, cisplatin 20mg/qm day 1–5) (4 cycles q3w) (November
2007–February 2008). After the ﬁrst cycle, febrile neutropenia
and septic shock occurred, but this was managed successfully.
Subsequent chemotherapy was delivered with granulocyte-colony
stimulating factor (G-CSF) prophylaxis–pegﬁlgrastim (Neulasta,
Amgen Europe B.V.(NLD)) and was uneventful. In April 2008,
complete extirpation of tumour residuumand retroperitoneal lym-
phadenectomy (RPLND) was performed and structures of mature
teratoma were revealed on ﬁnal histopathological examination
(Fig. 4). The patient experienced complete clinical remission for
almost 3.5 years. Disease progression occurred inMay 2011 involv-
ing the patient’s left adrenal as a solitary lesion. Increased level
of ßHCG (5.7 IU/l) was recorded and based on the MDT deci-
sion, the patient underwent surgery. Left adrenalectomy, partial
pancreatectomy and splenectomy were performed in order to
resect the adrenal lesion in close relation to the pancreatic tail
pseudocyst (a complication after the ﬁrst surgical intervention).
Metastatic embryonal carcinoma with high mitotic activity (more
than 10 mitoses per 10 high-power ﬁelds) was conﬁrmed on
histopathology. After the surgery, thepatient receiveda full 4 cycles
of 2nd-line VeIP chemotherapy q3w (vinblastin 0.11mg/kg day
Fig. 2. Retroperitoneal lymphonode inﬁltrated by embryonal carcinoma, HE stain
(100×).
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Fig. 3. Immunohistochemistry staining. (A) High proliferation activity Ki 67 stain (200×). (B) Positivity for CD 30 stain (400×). (C) Positivity for PLAP stain (400×). (D)
Positivity for CK AE 1/3 (400×).
Fig. 4. Mature teratoma, HE stain (100×).
1–2, ifosfamide 1.2 g/qm day 1–5, cisplatin 20mg/qm day 1–5)
plus G-CSF prophylaxis according to current EORTC (European
Organisation for Research and Treatment of Cancer) recommenda-
tion (August–October 2011). Second disease progression was diag-
nosed early after systemic therapy completion in February 2012
(Fig. 5). The PET/CT (positron emission tomography–computed
tomography) showed a lesion suspected to be a locoregional recur-
rence at the site of the left adrenalectomy, and metastatic mass
in the gastric fundus (Fig. 6). The patient underwent “desperation
surgery” in April 2012. Previous interventions made disecretion of
postoperative and tumour changes impossible and multivisceral
resection had to be performed (en bloc gastrectomy with distal
pancreatectomy, left nephrectomy and splenic ﬂexure resection).
On histopathological analysis, metastatic embryonal carcinoma
in both the gastric and colonic wall was found. No locoregional
recurrence was conﬁrmed, but the metastases had close rela-
tion to severe postoperative changes. Two cycles of 3rd-lineTIP
(paclitaxel 250mg/qm day 1, ifosfamid 1500mg/qm day 2–5, cis-
platin 25mg/qm day 2–5) salvage chemotherapy were delivered
(May–June 2012). The patient has had regular follow-up, is cur-
rently 34 months disease-free, and being carefully monitored in
order to detect relapse, development of secondary malignancies
and to assess cardiovascular events,whose frequency is higher after
combination chemotherapy for germ cell tumours.
3. Discussion
EGGCTs can be difﬁcult to distinguish from metastatic tumours
of testicular origin. Thorough testes investigation to rule out
testicular primary is mandatory because the unrecognised tumour
may be a source of relapse. In regressed tumours, moreover,
ﬁbrosis and inadequate blood supply may render chemotherapy
ineffective [2,10]. Although routine open testes biopsy is currently
CASE REPORT – OPEN ACCESS
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Fig. 5. The second disease progression pattern at CT scanning (2012).
(A) Metastatic lesion of gastric fundus.
(B) Suspected locoregional recurrence at the site of left adrenalectomy (colonic wall metastasis on ﬁnal histopathology).
(C) CT reconstruction of disease extent in sagittal plane.
not recommended [5], in our case, bilateral biopsy was performed
and proved negative.
Secondary surgery after 1st-line chemotherapy is performed in
45% of patients with nonseminomatous retroperitoneal EGGCTs
and currently is recommended for any postchemotherapy resid-
ual retroperitoneal mass ≥1 cm in nonseminomatous tumours
[11]. Resected residuum consists of necrotic tissue in more than
half of the patients, nondifferentiated tumour is found in 25%
and teratoma like in our case in another 16% [5,12]. The ade-
quacy of initial retroperitoneal lymph node dissection (RPLND) is
considered to be an independent predictor of disease-free sur-
vival in both low-stage and advanced nonseminomatous germ
cell tumours. The true incidence of retroperitoneal relapse after
RPLND is thought to be underestimated and occurs late [13].
In our case, neither of the two subsequent surgical interven-
tions showed disease relapse inside the operating ﬁeld of initial
RPLND, although this could not be ruled out preoperatively and
the patient in the end underwent multivisceral resection to assure
resection of all retroperitoneal disease. Histopathologically, the
ﬁrst disease relapse was localised within the left adrenal and
the second relapse in the gastric and in colonic wall. Only ﬁnal
histopathological examination could deﬁne the tumour origin pre-
cisely and distinguish it from postoperative changes after previous
surgeries.
In the retrospective analysis of Oldenburg et al. [14], late disease
recurrence after chemotherapy and radical RPLNDdoesnot exclude
prolonged survival. Twenty-two out of the 25 patients were con-
sidered tumour-free after treatment of the ﬁrst relapse. In seven
of them, the second relapse occurred, and the reported 10-year
postrelapse survival was 68% [14]. In this analysis, however, all
malignant germ cells tumours were included (seminomatous and
nonseminomatous) and only 4 cases were of primary extragonadal
origin. EGGCTs relapsing after initial chemotherapy have a poor
prognosis [5].
In our patient, tumour recurrence occurred after a long disease-
free interval of 3.5 years. Extirpation of recurrence within the left
adrenal plus 4 cycles of 2nd-line VeIP chemotherapywere followed
by early second tumour progression (9 months after the second
surgery and 6 months after completion of chemotherapy). As a
small proportion of patients with relapsed disease may achieve
durable remissionwith surgical resection alone [15,16], the patient
underwent multivisceral resection as the ﬁrst therapeutic step, fol-
lowed by 3rd-line adjuvant chemotherapy (2 cycles of TIP with
G-CSF prophylaxis).
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Fig. 6. The second disease progression pattern at PET/CT scanning (2012).
(A) Suspected locoregional recurrence at the site of left adrenalectomy (colonic wall metastasis on ﬁnal histopathology).
(B) Metastatic lesion of gastric fundus.
(C) PET/CT reconstruction of disease extent in coronal plane.
4. Conclusion
While standard 1st-line therapy in EGGCTs consists of
chemotherapy followed by surgery in patients with residual
mass, repeated tumour recurrences may pose a serious problem.
“Desperation surgery” with adjunctive salvage chemotherapy may
be an option for otherwise ﬁt patients, who are able to tolerate the
side-effects of repeated combined chemotherapy and surgery in
a second or 3rd-line treatment. Multidisciplinary decision-making
to ensure optimal timing of medical and surgical interventions in
patient with recurrent tumour is mandatory.
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